Sulindac vs celebrex

Non-Redox Inhibitors. ZD2138 by Zeneca, a selective, p.o.active 5-LO inhibitor of the methoxytetrahydropyran series, is devoid of redox and iron ligand-binding properties 156 ; . Despite its promising anti-inflammatory profile, Phase II clinical trials carried out in asthmatics had mixed results 145 ; , halting further clinical development of this compound. Whether ZD2138 exerts antiproliferative activity remains to be determined. FLAP Inhibitors, Indole Series. Extensive screening of indole compounds derived from COX inhibitors indomethacin and sulindac led to development of MK-886 by Merck 157 ; , the first FLAP inhibitor to reach clinical evaluation. MK-886 is believed to work by binding to an arachidonic acid binding site on FLAP, facilitating the transfer of the substrate to 5-LO 158 ; . Asthmatics administered 750 mg of MK-886 p.o. showed only 50% inhibition of LTB4 in ex vivo-stimulated whole blood and in urinary LTE4 levels 159 ; . On the basis of these data, further clinical development of MK-886 was discontinued. However, antiproliferative effects of MK-886 were observed recently at micromolar concentrations in malignant cells from patients with chronic myelogenous leukemia 141 ; and in human lung cancer cells 71 ; . On the basis of these preliminary findings, MK-886 may have some therapeutic potential as a chemopreventive agent. MK0591 represents a novel 2-indolealkanoic acid derivative and second-generation FLAP inhibitor developed by Merck 160 ; . Like MK-886, MK0591 blocks 5-LO activity by binding to FLAP, thereby preventing 5-LO translocation and activation. Despite its promising biochemical profile, development of MK0591 was discontinued after results from further clinical testing were below anticipated values. FLAP Inhibitors, Quinoline Series. Optimization of the 2-quinolylmethyloxy phenyl residue of Revlon's REV 5901 led to BAY-X1005, a potent, p.o. active inhibitor of 5-LO developed by Bayer AG to treat asthma 161, 162 ; . BAY-X1005 reportedly lacks 12-LO or COX inhibitory activity and is devoid of antioxidant activity 163 ; . The binding of BAY-X1005 to FLAP has been reported to directly correlate with the degree of LTB4 inhibition 164 ; . Development of BAY-X1005 for. Cytosolic PLA2, PGHS-1, and PGHS-2; dually phosphorylated ERK2 1; dually phosphorylated p38; p38; and PKC protein levels were measured by Western blotting using specific antibodies: monoclonal antibody to cPLA2 Santa Cruz Biotechnology, Inc., Santa Cruz, CA ; , monoclonal PGHS-1 and polyclonal PGHS-2 antibodies Cayman Chemical Co., Ann Arbor, MI ; , monoclonal antibodies specific for dually phosphorylated ERK2 1 Santa Cruz Biotechnology, Inc. ; , dually phosphorylated p38 and p38 antibodies New England Biolabs, Inc., Beverly, MA ; , and monoclonal antibody to PKC BD Transduction Laboratories, Lexington, KY ; . The appropriate species-specific second antibodies coupled to horseradish peroxidase were obtained from Amersham Pharmacia Biotech Arlington Heights, IL ; . The crude membrane preparations for cPLA2 and PKC translocation assays were prepared as described previously for PKC translocation 16 ; . Detection of phosphorylated cPLA2 by electrophoretic mobility retardation was carried out by SDS-PAGE using 10% polyacrylamide gels 15 cm long ; and running the samples until a 78-kDa prestained marker protein migrated at about 10 cm.

In vitro sulindac sulfide directly binds to the ras gene product p21ras in a non-covalent manner.
8. pharmacokinetics complicated by variable or incomplete absorption or absorption window, nonlinear pharmacokinetics, pre-systemic elimination high first-pass metabolism 70% and or complicated metabolic pathways, 9. unfavorable physicochemical properties, e.g., low solubility, instability, metastable modifications, poor permeability, etc., 10. documented evidence for bioavailability problems related to the drug or drugs of similar chemical structure or formulations, 11. where a exists, high ratio of excipients to active ingredients. 1. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis Part II ; . J. Natl. Cancer Inst. Bethesda ; , 90: 1609 1620, DuBois, R. N., Giardiello, F. M., and Smalley, W. E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am., 25: 773791, 1996. Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M., and Attali, P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101: 635 639, Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, J. A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 13131316, 1993. Hawkey, C. J. COX-2 inhibitors. Lancet, 353: 307314, 1999. Gupta, R. A., and DuBois, R. N., Aspirin, NSAIDs, and colon cancer prevention. Mechanisms? Gastroenterology, 114: 10951100, 1998. Kargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J., and O'Neill, G. Characterization of prostaglandin G H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tracts. Gastroenterology, 111: 445 454, Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., and Isakson, P. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv. Exp. Med. Biol., 400A: 167170, 1997. Xie, W., Chipman, J. G., Robertson, D. L., Erikson, R. L., and Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA, 88: 26922696, 1991. Fletcher, B. S., Kujubu, D. A., Perrin, D. M., and Herschman, H. R. Structure of the mitogen-inducible TIS10 gene and demonstration that the T1S10-encoded protein is a functional prostaglandin G H synthase. J. Biol. Chem., 267: 4338 4344, Hla, T., and Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA, 89: 7384 7388, Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 231: 232235, 1971. DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van de Putte, L. B. A., and Lipsky, P. E. Cyclooxygenase in biology and disease. FASEB J., 12: 10631073, 1998. Vane, J. R., and Botting, R. M. Overview--mechanisms of actions of anti-inflammatory drugs: In: J. Vane and R. Botting eds. ; , Improved Non-steroidal Antiinflammatory Drugs: COX-2 Enzyme Inhibitors, pp. 127. Boston: Kluwer Academic, 1996. 15. Zhang, Y., Shaffer, A., Portanova, J., Seibert, K., and Isakson, P. C. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J. Pharmacol. Exp. Ther., 283: 1069 1075, Smith, W. L., Garavito, R. M., and DeWitt, D. L. Prostaglandin endoperoxide H synthases cyclooxygenases ; -1 and -2. J. Biol. Chem., 271: 3315733160, 1996. Cohn, S. M., Schloemann, S., Tessner, T., Seibert, K., and Stenson, W. F. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J. Clin. Investig., 99: 13671379, 1997. Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G., Isakson, P. C., and Seibert, K. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA, 91: 3228 3232, Williams, C. S., And DuBois, R. N. Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol., 270: G393G400, 1996. 20. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 11831188, 1994. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., and Hla, T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55: 37853789, 1995 and surmontil.

Savings for prescription sulindac from canada is from 25-90% depending on strength and quantity and symlin. Figure 1: Sulindac sulfone inhibits cell proliferation and induces cell death in Caco-2 cells: A ; Cells were grown overnight and then treated with vehicle white squares ; , 50M sulindac sulfone black squares ; , 150M sulindac sulfone white triangles ; , 300M sulindac sulfone white circles ; or 600M sulindac sulfone black triangles ; . Cells were harvested after 1, 2, 4 and 6 days of adding the drug day 0 ; and counted. Total cells were plotted as a function of day. Each. In standard, manufacturer's recommended doses while performing duties in the absence of demonstrated adverse effects or of contraindications from the medical condition being treated. Individuals using these drugs over an extended period should be evaluated periodically regarding the underlying medical conditions as well as the effects of the drugs. The use of monoamine oxidase inhibitor for pain syndromes is not acceptable, regardless of dose. Antidepressants such as phenelzine Nardil ; and amitriptyline Elavil ; , carbamazepine Tegretol ; , or venlafaxine Effexor ; are sometimes used to treat conditions other than depression such as pain syndromes or hot flashes. The use of antidepressants in these circumstances is not acceptable, regardless of dose. In some cases the pain syndrome itself may not be acceptable. Osteoarthritis and Rheumatoid arthritis may be treated with the acceptable pain relievers and antiinflammatory agents noted above. Etanercept Enbrel ; and leflunomide Arava ; are normally acceptable for treatment of rheumatoid arthritis. Non-steroidal anti-inflammatory agents e.g., etodolac [Lodine], piroxicam [Feldene], sulindac [Clinoril], meloxicam [Mobic], and others noted above ; generally are acceptable in the absence of adverse effects. Agents such as gold Myochrysine ; , methotrexate, azathioprine Imuran ; , and other immunosuppressive agents are very potent drugs and require careful monitoring by experienced physicians. Acceptability for ATCS duties would depend on the circumstances of the specific case but may be possible. Infliximab Remicade ; , in combination with methotrexate, is a drug approved for use in moderate-to-severely active rheumatoid arthritis. It is given intravenously in three doses during drug initiation infusions on day-0, day-14 and day-42 ; then followed by infusions every 4-8 weeks. Medical restriction is required during the initial three-dose drug initiation plus two weeks total restriction is 8 weeks ; . Two weeks after dose-three of the drug initiation series, if there are no adverse side effects and the disease is under control, special consideration may be possible. When continuing treatment every 4-8 weeks is required, then the ATCS is medically restricted for 24-hours after each dose. The ATCS should promptly report any symptoms of headaches, dizziness, chest pain, swelling of mouth or throat, hives, itching, fever, rash, muscle or joint aches to the RFS. Because it is intended for severe, complicated forms of rheumatoid arthritis, the condition itself is likely to determine if the ATCS could receive medical clearance. Probenecid Benemid ; and allopurinol Zyloprim ; , for gout, are acceptable provided there are no adverse effects during a short trial. Acute, symptomatic gouty arthritis medically restricted until symptoms have subsided. If the condition is under control, these medications could be acceptable if a period of trial use demonstrates the absence of adverse effects. Humira Adalimumab ; is acceptable provided there is close monitoring by the treating physician an prompt notification to the Flight Surgeon of adverse side effects. Headaches. A history of migraine may serve as a basis for denial of medical clearance or preclude safety-related duties. However, when it is determined that the specific case can be waivered the following medications can be considered. Ergot preparations Wigraine, D.H.E. 45 ; , without sedatives, are generally acceptable when used for migraine. Methysergide Sansert ; , for prevention of attacks, is less often used now but could be acceptable if the ATCS remains under careful follow-up for adverse effects. Unfortunately, the use of methysergide suggests a degree of symptomatology and difficulty of control that could be incompatible with ATCS duties. The use of beta-blocking agents for migraine is acceptable. Newer drugs for treatment of acute attacks such as sumatriptan Imitrex ; , naratriptan Amerge ; , and zolmitriptan Zomig ; , are generally acceptable in the absence of adverse effects, but a and symmetrel.

Reagents. Celecoxib SC-58635 ; , SC-58125, and SC-560 were provided as kind gifts from G. D. Searle and Co. St. Louis, MO ; . Merck and Co. Rathway, NJ ; provided sulindac sulfide. DMSO EM Science, Gibbstown, NJ ; was used as the solvent. Concentrated drug stocks were diluted in DMEM Life Technologies, Inc., Grand Island, NY ; media before addition to cell cultures. The DMSO concentration in cultures was kept at 0.1%. Cell Culture. HCA-7 cells were a generous gift from Susan Kirkland. LLC and HCT-15 cells and HCT-116 cells were purchased from the American Type Tissue Collection Manassas, VA ; . MEF Derivation. Primary MEFs were derived by passing day 13.5 C57BL 6J mouse embryos through an 18-gauge needle. The cells were expanded over several days in DMEM supplemented with 10% FBS, 1% P S 1% L-glutamine. The cox-2 genotype of the MEF cell lines was verified as described previously 19 ; . Cell Counts. LLC cells were seeded into six-well plates at 2.5 104 cells well. Cells were treated in triplicate with DMSO or 25, 50, or 100 M celecoxib for 12 h and then harvested and counted using a Coulter counter model Z1 Coulter, Fullerton, CA ; . RESULTS In Vitro Viability Assay. The MTT assay was used to determine cell viability proliferation. This assay measures mitochondrial activity. MTT is a Treatment with Celecoxib Induces Concentration-dependent yellow-colored tetrazolium salt that is taken up and cleaved only by metabol- Apoptosis in Vitro. We have observed previously that a compound ically active cells, reducing it to a colored, water-insoluble formazan salt. The related to celecoxib, SC-58125, effectively inhibits the growth of LLC solubilized formazan product can be quantified via absorbance at 570 nm and colorectal cancer cells by 40% after 3 days of treatment in vitro.4 measured using a 96-well-format spectrophotometer, and the absorbance cor- When celecoxib became available, we sought to test its effect on the relates directly with cell number. Cells were plated at 1.5 104 cells well in growth of LLC cells. SC-58125-treated LLC cells remain morphologa 100- l volume in 96-well plates and grown for 24 h in DMEM supplemented ically unchanged; however, when LLC cells were treated with 50 M with 10% FBS. The indicated amount of test drug or DMSO in 1% FBS containing OptiMEM media was then added to the wells. At the indicated celecoxib for 12 h, they became rounded and detached from the culture dish Fig. 1A, left panel ; . As with SC-58125, we found that times, 10 l of MTT 5 mg ml ; was added, and the cells were incubated at 37C for 4 h. The tetrazolium crystals were solubilized by the addition of 10% celecoxib inhibited the growth of LLC cells but was much more SDS in 0.01 N HCl. After overnight incubation at 37C, the absorbance was potent. After only 12 h of treatment, the IC50 for celecoxib inhibition measured at 570 nm using a 96-well spectrophotometric plate reader Packard of cell number was 40 M Fig. 1A, right panel ; . The cytotoxicity of Instruments, Meriden, CT ; . Results are expressed as the mean SD of six celecoxib against LLC cells was also quantified using the MTT assay. wells. When celecoxib concentrations of 10 M were used, no effect on Prostaglandin Measurement. Subconfluent cell cultures were treated with cell viability or growth was observed.5 However, treatment for 12 h either celecoxib or SC-58125 for the indicated time. Thirty min before harwith 20 M celecoxib resulted in a dramatic decrease in cell viavesting media, arachidonate was added to the media to a final concentration of bility Fig. 1B ; . We next determined whether celecoxib also had 10 M. PGE2 was quantified as described previously 20 ; . Apoptosis Determination. The APO-Direct kit PharMingen, San Diego, potent cytotoxicity against two human colorectal carcinoma cell lines CA ; was used for quantitative evaluation of apoptosis in response to celecoxib HCT-15 and HCA-7 ; . Celecoxib had similar cytotoxic effects against treatment. This assay relies on the characteristic fragmentation of DNA during these cells with significant loss of viability at concentrations of 20 the apoptotic process. Terminal nucleotide transferase enzyme is used to M Fig. 1B ; . Once again, treatment of these cells with celecoxib for end-label the free 3 -OH of fragmented DNA using fluorescein-conjugated 3 days at concentrations of 10 M had no effect on cell viability. dUTP is used as the nucleotide for the exchange reaction. Flow cytometric To determine whether the cytotoxic effects of celecoxib were the detection of fluorescein-labeled fragmented DNA was conducted to quantita- result of induction of apoptosis, LLC, HCA-7, and HCT-15 cells were tively evaluate apoptosis in response to celecoxib treatment. Cells were seeded treated with 25 or 50 celecoxib. Apoptotic cells were identified by in 100-mm plates, and when 80% confluent cells were treated with DMSO, or TUNEL staining and the results analyzed by dual parameter flow 12.5, 25, or 50 M celecoxib in 1% FBS-supplemented OptiMEM media. cytometry using DNA content to identify the cell cycle position of Negative control cells were not treated; vehicle-treated cells had an amount of DMSO equivalent to the celecoxib-treated cells added. Cells were harvested cells undergoing apoptosis. Treatment with 50 M celecoxib caused after 12 h of treatment, washed in PBS twice then fixed in 1% paraformalde- significant apoptosis in all three cell lines with 88%, 37%, and 15% of hyde for 15 min and permeabilized by the addition of ice-cold 70% ethanol. LLC, HCA-7, and HCT-15 cells, respectively, undergoing apoptosis The labeling reaction was performed according to the manufacturer's recom- Fig. 2 ; . We found that LLC and HCA-7 cells undergoing apoptosis mendations, with the exception that 2 106 cells condition were used. After contained 4 N DNA content, suggesting that arrest at the G2-M stage labeling, cells were washed three times in PBS, then resuspended in 1 ml the cell cycle was occurring. In contrast, apoptotic HCT-15 cells propidium iodide staining solution 5 g ml propidium iodide, 40 g ml contained a subdiploid DNA content after celecoxib treatment, sugRNASE A, in 1 PBS ; . Cells were then filtered through 50- m mesh gesting that apoptosis was occurring when the cells contained 2 N immediately before analysis on a Becton Dickinson FACScan flow cytometer. DNA. The induction of apoptosis was confirmed by the detection of Gating on FL2-width was used to exclude aggregates, and 104 gated events oligonucleosomal cleavage of DNA in LLC and HCA-7 cells after were collected and analyzed. 5 Xenograft Model of Tumor Biology. HCA-7 cells were grown on plastic treatment with 50 M celecoxib for 6 h. culture dishes according to standard cell culture techniques 7 ; . The cells were 5 trypsinized and resuspended in sterile PBS, then pelleted by brief centrifugaData not shown. 6046.

Sulindac blood pressure

Cough drops and pregnancy, genetic testing bipolar, randomized controlled trial consort, hormone supplements and heart arrhythmia. Corneal transplant statistics, galactosemia prevalence, hypertrophy more condition_treatment and dioxin poisoning or paroxysmal nocturnal hemoglobinuria.

Sulindac dosage

Sulindac side effects treatment

Sulindac 200 mg nsaids, sulindac price, ic sulindac 200, sulindac among patients and sulindac 200mg info. Sulindac and aspirin, how does sulindac work, history of sulindac and sulindac blood pressure or sulindac dosage.